SURVIVAL BENEFIT OF NEOADJUVANT CHEMOTHERAPY IN RESECTABLE PANCREATIC CANCER - NEED BOTH ENDS OF THE SANDWICH

被引：0
|
作者：
Kim, Rachel C.
Allen, Kara A.
Roch, Alexandra M.
Butler, James
Ceppa, Eugene P.
House, Michael G.
Zyromski, Nicholas J.
Nakeeb, Attila
Schmidt, C. Max
Nguyen, Trang
机构：
来源：
GASTROENTEROLOGY | 2023年 / 164卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1172
引用
收藏
页码：S1510 / S1510
页数：1
相关论文
共 50 条
  • [21] Neoadjuvant chemotherapy in borderline resectable pancreatic cancer: A case report
    Palmarocchi, Maria Celeste
    Canger, Ruben Carlo Balzarotti
    Saletti, Piercarlo
    ONCOLOGY LETTERS, 2017, 13 (06) : 4445 - 4452
  • [22] Optimal Management of Resectable Pancreatic Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
    Rieser, C.
    Zenati, M.
    Narayanan, S.
    Bahary, N.
    Lee, K. K.
    Paniccia, A.
    Bartlett, D.
    Zureikat, A.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (SUPPL 1) : S188 - S188
  • [23] Survival Benefit after Shifting from Upfront Surgery to Neoadjuvant Treatment in Borderline Resectable Pancreatic Cancer
    Jeon, Hyun Jeong
    Lim, Soo Yeun
    Jeong, Hyejeong
    Yoon, So Jeong
    Kim, Hongbeom
    Shin, Sang Hyun
    Heo, Jin Seok
    Han, In Woong
    BIOMEDICINES, 2023, 11 (08)
  • [24] Survival After Neoadjuvant Chemotherapy in Borderline Resectable Disease is Similar to That of Upfront Resectable Pancreatic Adenocarcinoma
    Chawla, A.
    Molina, G.
    Pak, L.
    Wang, J.
    ANNALS OF SURGICAL ONCOLOGY, 2019, 26 : S150 - S150
  • [25] ASO Author Reflections: Is There an Extra Benefit of Adding Neoadjuvant Radiotherapy to Chemotherapy in Patients with (Borderline) Resectable Pancreatic Cancer?
    Yun, Won-Gun
    Jang, Jin-Young
    ANNALS OF SURGICAL ONCOLOGY, 2025, 32 (04) : 2859 - 2860
  • [26] Erratum to: Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival
    J. Bart Rose
    Flavio G. Rocha
    Adnan Alseidi
    Thomas Biehl
    Ravi Moonka
    John A. Ryan
    Bruce Lin
    Vincent Picozzi
    Scott Helton
    Annals of Surgical Oncology, 2014, 21 (5) : 1538 - 1538
  • [27] Multi-agent neoadjuvant chemotherapy improves response and survival in patients with resectable pancreatic cancer.
    Maramara, Taylor
    Huston, Jamie
    Shridhar, Ravi
    Meredith, Kenneth L.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [28] Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
    Roberto Alva-Ruiz
    Lavanya Yohanathan
    Jennifer A. Yonkus
    Amro M. Abdelrahman
    Lindsey A. Gregory
    Thorvadur R. Halfdanarson
    Amit Mahipal
    Robert R. McWilliams
    Wen Wee Ma
    Christopher L. Hallemeier
    Rondell P. Graham
    Travis E. Grotz
    Rory L. Smoot
    Sean P. Cleary
    David M. Nagorney
    Michael L. Kendrick
    Mark J. Truty
    Annals of Surgical Oncology, 2022, 29 : 1579 - 1591
  • [29] Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
    Caroline J. Rieser
    Mazen Zenati
    Sowmya Narayanan
    Nathan Bahary
    Kenneth K. Lee
    Alessandro Paniccia
    David L. Bartlett
    Amer H. Zureikat
    Annals of Surgical Oncology, 2021, 28 : 6264 - 6272
  • [30] Optimal Management of Resectable Pancreatic Head Cancer in the Elderly Patient: Does Neoadjuvant Therapy Offer a Survival Benefit?
    Rieser, Caroline J.
    Zenati, Mazen
    Narayanan, Sowmya
    Bahary, Nathan
    Lee, Kenneth K.
    Paniccia, Alessandro
    Bartlett, David L.
    Zureikat, Amer H.
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (11) : 6264 - 6272
12345